May 26th, 2023 (Shanghai) — We are glad to announce that Guohuang Fan, the Founder, President, CEO of Immunophage Biomedical, has been invited to present at ACCESS CHINA Boston Forum on June 4th. ACCESS CHINA Biotech Forum is the largest corporate access event between Asia and the western biopharma industry.
Please contact us if you would like to have 1 on 1 meeting with Immunophage Biomedical.
About Immunophage Biomedical
Immunophage Biomedical Co Ltd is a global-clinical stage biopharmaceutical company focusing on innovating and developing the next generation drug for unmet medical needs. Founded and managed by seasoned executives in the biopharma industry, Immnophage is backed by many renowned investors.
The company has developed a pipeline of globally innovative molecules, covering a wide range of innovative targets with a particular focus on oncology, autoimmune diseases and neurodegenerative diseases.
The company has built strong capability for both small and large molecular platforms. Based on our own platform and effort, currently, we have two self-developed assets in clinical stage (IPG1094 and IPG7236). Meanwhile, we have a number of global leading innovative molecules under research and development. The company endeavors to advance at least two potentially innovative and differentiated global molecules into the clinic each year, providing clinical benefits to patients worldwide. We have established a Shanghai R&D center, a wholly-owned subsidiary in Australia and a wholly-owned subsidiary in the United States to realize the layout of globalization since 2018. The company was recognized as a national high-tech enterprise in 2020 and selected as a cultivated unicorn enterprise in Nanjing in 2021.
公司简介
南京艾美斐生物医药科技有限公司是一家临床阶段的生物制药公司，专注于创新药研发。艾美斐由两位生物制药行业经验丰富的高管创立和管理，并获得许多知名投资者的支持。
公司注重研究疾病的致病机理，深入发掘新靶点，围绕恶性肿瘤、自身免疫性疾病、神经退行性疾病等重大疾病开展新药开发。
公司拥有小分子和大分子药物筛选和测试平台进行药物开发，目前第一梯队两个项目IPG1094&IPG7236处于临床Ⅰ-Ⅱ期阶段。公司致力于每年将至少两种具有创新潜力和差异化的全球分子推向临床，为全球患者提供新的支持。
艾美斐医药于2018和2021年分别成立上海研发中心、澳大利亚全资子公司和美国全资子公司，以实现全球化布局。公司于2020年被认定为国家高新技术企业，2021年入选南京市培育独角兽企业。
About the speaker
Over 28 years of research experience in cancer, autoimmune diseases and neurodegenerative diseases, with over 60 papers published in peer-reviewed international journals, and 20 patents MD, Ph.D., Shanghai Jiao Tong University School of Medicine, 6 years of postdoctoral trainings in Chinese Academy of Sciences; the University of Wuerzburg, Germany; Vanderbilt University, USA 8 years of tenure-track faculty appointments in Vanderbilt University, Meharry Medical College and Virginia Commonwealth University School of Medicine, distinguished professor at the Shanghai Institute of Health Sciences, CAS and Tongji University.
6 years of experience in GSK R&D China, as division head and project leader, having successfully moved several projects to clinical trials National Natural Science Award (second prize), Chinese Medical Science and Technology Award (first prize), Shanghai Science and Technology Progress Award (first prize), NIH Special Neuroscience Award in the United States. Selected into the “Hundred Talents Plan” of CAS(2005), Nanjing Science and Technology Top Expert CLASS A (2021).
专家简介
医学专家，药理学专家，国家自然科学奖获得者，德国洪堡学者，中国科学院“百人计划”学者；
拥有28年恶性肿瘤和神经退行性病变等重大疾病的药理学研究经验，在国际重要期刊上发表60余篇研究论文，获得20余项发明专利；
上海交大医学博士，之后分别于中科院上海细胞生物学研究所、德国维尔茨堡大学医学院和美国范德堡大学医学院深造6年；
在国外知名高校任教8年，包括美国范德堡大学、美国梅哈里医学院助理教授（终身制），美国弗吉尼亚联邦大学医学院终身副教授，并长期兼任中科院上海健康科学研究所、同济大学教授和博士生导师；
在GSK中国研发中心管理新药研发团队的6年间，领导过多项重大疾病领域新药的临床前研究和临床试验；
曾先后荣获国家自然科学奖（二等奖）、中华医学科技奖（一等奖）、上海市科技进步奖（一等奖）、美国NIH特别神经科学奖，入选中科院“百人计划”（2005），南京科技顶尖专家A类（2021）。
About ACCESS CHINA Boston Forum
“ACCESS CHINA – Boston Forum @BIO” is scheduled to be held on June 4th and June 13th-15th, 2023, in Boston and online, respectively. This event is expected to be the largest Asia-themed gathering during the BIO Convention 2023. The main theme of the forum is “Building Effective Partnerships in Asia: Strategies for Collaboration and Growth”. During the forum, we will cover a range of key topics include drug innovation, market trends, partnership models, and best practices for successful collaborations, etc.
Conference Name: ACCESS CHINA – Boston Forum @BIO
Date & Time: June 4, Sun. (Boston) and June 13-15 (Online)
Content: Keynote Speeches, Panel Discussion, Company Presentations, ChemPartner-ACCESS CHINA Dinner Reception
Scale: Expected 1000 participants Online, 150 participants onsite; 100 company roadshows
Participants: Pharma/Biotech senior management and BDs, investors.
View more information at https://biotochina.org/
关于药通中国-波士顿论坛
“ACCESS CHINA 药通中国-波士顿论坛@BIO”将于2023年6月4-15日在波士顿及线上举行的。此次论坛将是BIO Convention 2023大会期间最大的亚洲主题交流活动。在过去3年时间，药通中国已成功举办13届线上线下活动，帮助近千家公司在药通平台上展出。
大会名称：药通中国-波士顿论坛@BIO
大会日期：2023.6.4（周日，波士顿） 2023.6.13-15（线上）
大会内容：主题演讲、圆桌讨论、海内外优质项目路演、睿智医药-药通中国招待晚宴
大会规模：预计线上1000参会者； 线下150参会者; 100场公司路演
参会观众：海内外医药企业（药企及Biotech）高管及BD、基金高管
查看更多信息： https://biotochina.org/
MORE INFORMATION
Contact US
Register ACCESS CHINA online, please visit: ACCESS CHINA Biotech Forum
For more information, please contact:
Wendi Xiang
Wxiang@yafocapital.com
BioToChina.org 